Comparative Pharmacology
Head-to-head clinical analysis: ACETAZOLAMIDE versus ACETAZOLAMIDE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETAZOLAMIDE versus ACETAZOLAMIDE SODIUM.
ACETAZOLAMIDE vs ACETAZOLAMIDE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibition of carbonic anhydrase, primarily in the proximal renal tubule, reducing hydrogen ion secretion and increasing bicarbonate, sodium, potassium, and water excretion. Also reduces aqueous humor formation via ocular carbonic anhydrase inhibition.
Acetazolamide is a carbonic anhydrase inhibitor. It reversibly inhibits the enzyme carbonic anhydrase, which catalyzes the reversible hydration of carbon dioxide and dehydration of carbonic acid. This results in increased excretion of bicarbonate, sodium, potassium, and water in the urine, leading to metabolic acidosis. Additionally, it reduces aqueous humor secretion in the eye, lowering intraocular pressure, and can decrease cerebrospinal fluid production.
250-500 mg orally twice daily or 250 mg intravenously twice daily; for edema, 250-375 mg orally once daily; for altitude sickness, 250 mg orally every 8-12 hours.
Adult: 250-500 mg IV or IM every 12-24 hours; for edema, 250-375 mg IV once daily in morning. For glaucoma, 250-1000 mg IV or IM daily in divided doses.
None Documented
None Documented
Clinical Note
moderateAcetazolamide + Atorvastatin
"The risk or severity of adverse effects can be increased when Acetazolamide is combined with Atorvastatin."
Clinical Note
moderateAcetazolamide + Diclofenamide
"The risk or severity of adverse effects can be increased when Acetazolamide is combined with Diclofenamide."
Clinical Note
moderateAcetazolamide + Fosphenytoin
"The risk or severity of adverse effects can be increased when Acetazolamide is combined with Fosphenytoin."
Clinical Note
moderateTerminal half-life approximately 10–15 hours; prolonged in renal impairment (up to 30+ hours).
10-15 hours (prolonged in renal impairment; cirrhosis increases t1/2 to 20-30 h).
Renal: ~90% unchanged drug via tubular secretion and glomerular filtration; minor biliary/fecal (<2%).
Primarily renal (90% unchanged via tubular secretion). <2% biliary/fecal.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor
Acetazolamide + Phenytoin
"The risk or severity of adverse effects can be increased when Acetazolamide is combined with Phenytoin."